KPE® - Certificate Program (1 Month)

Recent Articles

• Understanding on India’s Revised Patent Rules On Priority filing w.e.f 19 October, 2020
• Insight of BioInvent’s licensing deal of anti-FcγRllB antibody BI-1206 to CASI Pharmaceuticals
• Case Study – Inmazeb: USFDA Approval of first ebola medicine
• Pfizer’s Hospital Business acquires Arixa Pharma
• Insight on Veklury’s clinical and strategic pathway for USFDA approval for Covid-19
• Case Study: Rinvoq’s brand Dermatology market expansion strategy
• Sobrera, Recipharm Collaborate to Advance Alcohol Use Disorder Treatment
• Centaur Pharma launches WOXheal to treat diabetic foot ulcers
• FSD Pharma gets US FDA nod to begin phase 2 study of FSD201 to treat COVID-19
• AbbVie’s Elezanumab receives US FDA orphan drug and fast track designations
• USFDA granted expanded access to investigational ERK inhibitor ulixertinib
• Case Study – Strategic Insight on Gilead and Immunomedics $21 Billion Deal
• Insight on USFDA approval of pralsetinib to treat non-small lung cancer
• What is hybrid clinical trial?
• Strides Pharma to acquire 54% stake in SteriScience
• Aurobindo Pharma partners with BIRAC to develop Covid-19 vaccine
• Insight on First approved COVID-19 vaccine Sputnik V
• Novavax and Serum Institute of India – licensing agreement for Development and Commercial Collaboration
• Novavax reports positive results from phase 1 trial of COVID-19 vaccine candidate, NVX-CoV2373 with Matrix-M
• Lupin gets exclusive rights to market and distribute 2 complex injectable assets from ForDoz Pharma